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Background: In non-small cell lung cancer (NSCLC), interstitial hypertension is a barrier to chemotherapy delivery,
and is mediated by platelet derived growth factor receptor (PDGFR). Antagonizing PDGFR with imatinib may
improve intra-tumoral delivery of paclitaxel, increasing response rate (RR).
Methods: This single-stage, open-label phase II study evaluated pulse dose imatinib and weekly paclitaxel in elderly
patients with advanced NSCLC. Eligible patients were aged ≥ 70 with untreated, stage IIIB-IV NSCLC and ECOG
performance status 0-2. Primary endpoint was RR. Secondary endpoints included median progression free and
overall survival (PFS, OS) and correlatives of PDGFR pathway activation. Baseline Charlson Comorbidity Index (CCI)
and Vulnerable Elder Survey-13 (VES-13) were correlated with outcomes.
Results: Thirty-four patients with median age 75 enrolled. Eleven of 29 (38%) were frail by VES-13 score. Overall RR
was 11/34 (32%; 95% CI 17%-51%), meeting the primary endpoint. Median PFS and OS were 3.6 and 7.3 months,
respectively. High tumoral PDGF-B expression predicted inferior PFS. Frail patients by VES-13 had significantly worse
median PFS (3.2 vs. 4.5 months; p=0.02) and OS (4.8 vs. 12 months; p=0.02) than non-frail.
Conclusions: The combination of imatinib and paclitaxel had encouraging activity as measured by the primary
endpoint of RR. However, PFS and OS were typical for elderly patients treated with single agent chemotherapy and
the regimen is not recommended for further study. Adjunct imatinib did not overcome the established association
of tumoral PDGF-B expression with inferior PFS. VES-13 was a powerful predictor of poor survival outcomes. Frailty
should be further studied as a predictor of non-benefit from chemotherapy.
Trial Registration: ClinicalTrials.gov NCT01011075
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Platelet-derived growth factor, Frailty, Vulnerable elder surveyBackground
Platelet-derived growth factor receptor (PDGFR) and its
ligand, PDGF, constitute a tyrosine kinase signaling family
involved in angiogenesis, inhibition of apoptosis, and regu-
lation of interstitial fluid pressure (IFP) [1]. PDGF is a di-
meric protein with 4 isoforms, which binds to the* Correspondence: baumanje@upmc.edu
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reproduction in any medium, provided the orextracellular domain of two structurally related tyrosine
kinase receptors, PDGFR-α and PDGFR-β. A classic target
of PDGF is the stromal fibroblast which expresses both α
and β receptors, predominantly β-type [2]. IFP in both
normal and malignant tissues is actively regulated by
fibroblast signaling through PDGFR-β. In solid tumors,
elevated IFP is a barrier to delivery of chemotherapy, im-
peding transcapillary drug transport due to Starling forces
[3]. Elevated IFP is caused by a dysfunctional stroma, fea-
turing structurally abnormal capillaries and lymphatics,
desmoplasia, and contraction of the interstitial matrix by
fibroblasts [4]. The phenotype of interstitial hypertensionl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mesylate (Novartis; Basel, Switzerland) is a synthetic tyro-
sine kinase inhibitor targeting Bcr-Abl, c-Kit and PDGFR.
In murine thyroid cancer xenografts, adjunct imatinib
decreased IFP, increased uptake of epothilone B or pacli-
taxel, and increased anti-tumor effects relative to chemo-
therapy alone [5,6]. In non-small cell lung cancer
(NSCLC) xenografts, imatinib decreased phosphorylated
PDGFR-β, vascular endothelial growth factor, and IFP
while increasing intratumoral delivery of docetaxel or lipo-
somal doxorubicin [7].
Cytoplasmic expression of PDGF occurs in the majority
of NSCLC and is a negative prognostic indicator, while
PDGFR-β is expressed universally by tumor stroma [8-10].
Co-expression of PDGF and PDGFR-β raises the plausibil-
ity of a paracrine loop mediating interstitial hypertension
and chemotherapy resistance. Elevated IFP up to 25
mmHg has been described in lung tumors, which may
underlie low response rates to chemotherapy [11]. We
hypothesized that antagonism of PDGFR-β with imatinib
could increase the therapeutic index of weekly paclitaxel.
Paclitaxel is a mitotic inhibitor which independently
enhances perfusion and oxygenation, and decreases IFP
[12,13]. Paclitaxel is superior to best supportive care in
first line management of advanced NSCLC [14] and is
indicated in combination with platinum for fit, age-
unselected patients. A taxane is an accepted single agent
standard in elderly patients with advanced NSCLC
[15,16]. Here, we report the final results from a phase II
clinical trial evaluating the combination of weekly pacli-
taxel and pulse dose imatinib in elderly patients with
advanced, chemotherapy-naïve NSCLC.
Methods
This multi-center study was approved by the institutional
review boards of the University of Washington-Fred
Hutchinson Cancer Research Center and the University
of New Mexico. The clinical trial was publicly registered
at ClinicalTrials.gov, NCT01011075. Key eligibility cri-
teria included: age ≥ 70, diagnosis of advanced NSCLC
(stage IIIB with pleural effusion or IV [17]); measurable
disease according to modified RECIST criteria version 1.0
[18]; Eastern Cooperative Oncology Group performance
status (ECOG-PS) 0 to 2; adequate organ function. Key
exclusion criteria included: prior chemotherapy for
advanced NSCLC; uncontrolled brain metastases; symp-
tomatic neuropathy (Grade ≥ 2); serious or uncontrolled
concomitant medical disorder. All patients provided
written informed consent.
Patients were treated with up to six 28-day cycles of
imatinib and paclitaxel. Paclitaxel 90 mg/m2 was admi-
nistered intravenously on days 3, 10, and 17 of each 28-
day cycle. Imatinib 600 mg daily was administered orally
in 4-day pulses bracketing each paclitaxel infusion (days1-4, 8-11, 15-18), adapted from the phase I design [19].
Pulse dose imatinib was selected based upon the theor-
etical mechanism of action of PDGFR-β blockade,
pharmacokinetics of IFP response in xenografts, and in-
ability to escalate paclitaxel with continuous imatinib in
phase I. The dose limiting toxicity was neutropenia, con-
sistent with earlier reports that continuous dose imatinib
resulted in prohibitive hematologic toxicity when com-
bined with cisplatin-irinotecan or gemcitabine [20,21].
The study incorporated a single-stage, open label,
phase II design. An interim toxicity analysis was planned
after the first 8 patients completed one cycle. The pri-
mary endpoint was response rate (RR) as measured by
modified RECIST criteria version 1.0 [18]. The assumed
null RR to single agent paclitaxel was 15%, as in CALGB
9730 [22], and a RR considered worthy of further study
was 35%. Patients inevaluable for response were consid-
ered non-responders. A sample size of 35, with 33 eli-
gible patients had 87% power to detect a true RR of 35%,
and a 5% chance of falsely rejecting the null rate of 15%.
The decision rule rejected the null hypothesis if ≥ 9 of
33 patients responded. Secondary efficacy endpoints
included overall survival (OS), progression-free survival
(PFS), and toxicity. Survival outcomes were analyzed by
Kaplan-Meier methodology. Toxicity was described by
National Cancer Institute Common Terminology Cri-
teria for Adverse Events, version 3 [23]. Case report
forms captured all grade ≥3 toxicities, any grade neur-
opathy or edema, and any grade event resulting in dose
reduction or delay.
Exploratory objectives included measurement of tumor
biomarker expression and assessment of patient comorbid-
ity and frailty. Archived, formalin-fixed, paraffin-embedded
(FFPE) tumor specimens were collected retrospectively for
immunohistochemical (IHC) analysis. Staining for PDGF-B
(Clone N-30; Santa Cruz Biotechnology, Inc., Santa Cruz,
CA) and PDGFR-β (Clone Y92; Epitomics, Burlingame,
CA) was performed by an optimized IHC staining proto-
col. Normal human placental tissue previously shown to
be positive for PDGF-B and PDGFR-β was used as a
positive control; the same tissue, incubated with an
isotypic-matched antibody, was used as the negative con-
trol. Cytoplasmic PDGF-B and stromal PDGFR-β expres-
sion were graded using an H-score obtained by
multiplying staining intensity (0 negative; 1+, weak; 2+,
moderate; 3+, strong) by the percent of target cells with
positive cytoplasmic or nuclear staining (0 to 100%) [24].
The study pathologist was blinded to outcome measures.
Maximum likelihood estimates were conducted to de-
scribe the relationship of tumoral PDGF-B expression to
RR, PFS and OS. The Vulnerable Elder Survey-13 [25]
(VES-13) and Charlson Comorbidity Index [26] (CCI) re-
spectively measured baseline frailty and comorbidity, to
explore whether such measures could predict toxicity or
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of ≥ 3, the threshold associated with functional decline
and mortality in the ambulatory, non-oncologic geriatric
population [27]. We planned combined variable log-rank
tests to determine whether a combination of VES-13,
CCI, and/or ECOG-PS would perform better than a sin-
gle variable in predicting toxicity or survival.
Results
Thirty-four patients enrolled from September 2006
through April 2010 at three participating sites, including
University of Washington, University of New Mexico
and Puget Sound Oncology Consortium. Baseline patient
characteristics are presented in Table 1. Median number
of paclitaxel cycles was 2 (range 0 – 6). Nine patients
(26%) required reduction of imatinib, with the mostTable 1 Baseline characteristics
Characteristic Number (%)1
Age (Years)
Median 74.5
Range 70-86
Sex
Male 23 (68%)
Female 11 (32%)
Histology
Adenocarcinoma 16 (47%)
Squamous 10 (29%)
Poorly differentiated 6 (18%)
Large cell/other 2 (6%)
Stage2
IIIB 8 (24%)
IV 26 (76%)
ECOG Performance Status (n=32)
0 10 (29%)
1 18 (53%)
2 4 (11%)
Charlson Comorbidity Score (n=33)
Median 1
Range 0-7
VES-13 Score (n=29)
Median 1
Range 0-8
VES ≥ 3 (Frail) 11 (38%)
Tumor PDGF score (n=14)3
Median 75
Range 0-300
1Number(percent) unless units otherwise specified.
2American Joint Committee on Cancer, 6th ed.
3Score: Intensity of cytoplasmic staining x percent of tumor cells.common reasons including neutropenia, neuropathy,
and fatigue. Four patients (15%) required reduction of
paclitaxel for neuropathy, elevated bilirubin, or fatigue.
Treatment-emergent grade 3 or higher adverse events
are summarized in Table 2. The most common grade ≥
3 nonhematologic toxicities were fatigue, cardiac events,
gastrointestinal events, infection, and rash. Cardiac ad-
verse events included 2 episodes of grade 3 systolic dys-
function possibly related to imatinib, and 2 deaths from
myocardial infarction and cardiac arrest attributed to
pre-existing coronary artery disease. One death from in-
fection and one from pneumonitis were considered
protocol-related.
Six patients were inevaluable for the primary endpoint,
due to withdrawal or death prior to first response assess-
ment. Per predefined intent-to-treat analysis, such
patients were counted as non-responders. Eleven of 34
patients responded, with an overall RR of 32% (95% CI
17.4 – 50.5%), excluding the null rate of 15% and meet-
ing the primary endpoint. Twelve patients had stable
disease, with an overall disease control rate of 68%. Me-
dian PFS was 3.6 months, and median OS was 7.3
months (Figure 1).
Eighteen patients submitted archived tumor for cor-
relative studies, and 14 specimens contained viable
tumor for analysis of PDGF-B and PDGFR-β.Table 2 Grade ≥ 3 adverse events
Toxicity Grade 3 Grade 4 Grade 5 Total
Hematologic 7 (21%)
Anemia 1 (3%) 0 0 1 (3%)
Neutropenia 4 (12%) 1 (3%) 0 5 (15%)
Febrile Neutropenia 0 1 (3%) 0 1 (3%)
Thrombocytopenia 0 0 0 0
Nonhematologic
Cardiac 4 (12%)
Systolic dysfunction 2 (6%) 0 0 2 (6%)
Cardiac arrest 0 0 1 (3%) 1 (3%)
Myocardial infarction 0 1 (3%) 1 (3%) 2 (6%)
Edema 1 (3%) 0 0 1 (3%)
Fatigue 10 (29%) 1 (3%) 0 11 (32%)
Infection 3 (9%) 0 1 (3%) 4 (12%)
Gastrointestinal 4 (12%)
Constipation 2 (6%) 0 0 2 (6%)
Diarrhea 2 (6%) 0 0 2 (6%)
Pulmonary 3 (9%)
Embolism 1 (3%) 0 0 1 (3%)
Pneumonitis 0 0 1 (3%) 1 (3%)
Pneumothorax 0 1 (3%) 0 1 (3%)
Bladder/Kidney stone 2 (6%) 0 0 2 (6%)
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Figure 1 Progression-Free and Overall Survival.
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http://www.biomedcentral.com/1471-2407/12/449Representative digital photomicrographs are presented
in Figure 2. PDGF-B expression score was indirectly
associated with PFS (p=0.03), with higher tumoral ex-
pression portending earlier progression. PDGF-B score
was not associated with RR or OS. PDGFR-β was
present universally in tumor stroma with variable inten-
sity; no membranous or cytoplasmic staining was
observed in epithelial cells. Stromal expression scores
were not associated with RR, PFS or OS.
Measures of performance status, frailty and comorbid-
ity did not predict RR. However, frailty was significantly
associated with both PFS and OS (Figure 3). At baseline,Figure 2 PDGF-B and PDGFR-β Immunohistochemistry. Legend: Repres
(D-F) in lung tumors (A, B, D, E) and human placenta (C, F). Inset shows th11 of 29 patients with available VES-13 scores met the
definition for frailty. Only 3 frail patients had an ECOG-
PS of 2; the remaining 8 had an ECOG-PS of 0 or 1.
Frail patients had significantly worse median PFS (3.2 vs.
4.5 months; p=0.02) and OS (4.8 vs. 12 months; p=0.02)
than non-frail. Frailty did not significantly predict tox-
icity. ECOG-PS was associated with OS, however not
PFS or toxicity. Patients with ECOG-PS of 0 or 1 vs. 2
had median OS of 8.3 vs. 3.2 months (p=0.04). The CCI
did not predict PFS, OS or toxicity. An exploratory,
combined variable log rank test identified the combin-
ation of VES and ECOG-PS as the best predictor ofentative immunohistochemical staining of PDGF-B (A-C) and PDGFR-β
e same placental tissue stained with an isotype-matched antibody.
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Figure 3 Progression-Free and Overall Survival According to VES-13 Frailty Score.
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defined as those with VES score < 3 (non-frail) and
ECOG-PS of 0 or 1; the poor risk group included all
others. Median PFS in the good vs. poor risk group was
4.5 vs. 3.2 months (p=0.01). Similarly, median OS was
12.0 versus 4.0 months (p=0.01).
Discussion
In elderly patients with advanced NSCLC, first line treat-
ment with the combination of intermittent, pulse dose
imatinib and weekly paclitaxel demonstrated encour-
aging activity as measured by the primary endpoint of
RR. As defined, the study fulfilled its primary endpoint;
however two caveats warrant discussion. First, although
RR was intriguing, both PFS and OS were numerically
similar to values seen in the elderly population treated
with single agent chemotherapy [28,29]. While the RR
indicates that pulse dose imatinib may increase early
anti-tumor effects from paclitaxel, the typical PFS and
OS suggest that enhanced efficacy is not sustained. Sec-
ond, several cautionary studies have now been published
evaluating the combination of continuous dose imatinib
and a related taxane, docetaxel, in solid tumors includ-
ing NSCLC [30,31], breast cancer [32], androgen-
independent prostate cancer [33], and ovarian cancer
[34]. In these studies, patients were exposed to uninter-
rupted daily imatinib. These trials described poor toler-
ance; 7 of 8 were halted early for toxicity or lack of
efficacy. Specifically in NSCLC, concern was raised for
antagonism between continuous dose imatinib and doce-
taxel, due to a low observed RR [30].
Concurrent inhibition of PDGFR-β to overcome intersti-
tial hypertension and improve tumoral delivery of chemo-
therapy has strong preclinical merit. Adjunct imatinib
significantly decreased IFP and increased drug uptake in
numerous solid tumor xenografts; efficacy measurablyincreased when considering apoptosis, proliferation rate,
or tumor volume [5,6,35]. Imatinib may also serve an anti-
angiogenic role, as PDGF-B signaling from endothelial
cells maintains homeostasis of the pericyte. In tumor ca-
pillaries, pericytes have a structurally abnormal association
with endothelial cells resulting in excess permeability,
microaneurysms and impaired blood flow [36,37]. In
tumor models, PDGF sequestration reduced pericyte
coverage in tumor blood vessels; abnormal vessels were
selectively pruned, normalizing the vascular phenotype
[38,39]. In NSCLC xenografts, disruption of PDGF signal-
ing similarly normalized tumor vasculature, enhancing up-
take and efficacy of cyclophosphamide [40]. However, in
the same model PDGF disruption without chemotherapy
resulted in a wider perivascular sleeve of tumor cells, a
higher index of tumor proliferation, and enhanced tumor
growth. These paradoxical results caution that, while
PDGFR-β blockade may be an effective adjunct to chemo-
therapy, alone it may be pro-proliferative due to improved
circulatory efficiency. These preclinical findings may ex-
plain why the RR in our study stands in contrast to results
from continuous dose imatinib and docetaxel in NSCLC.
In our study, patients were exposed to 12 days of imatinib
per 28-day cycle, limiting isolated PDGFR- β inhibition. In
addition, pulse dose imatinib may have minimized pro-
posed mechanisms of antagonism including arrest of
tumor cells at the G0-G1 checkpoint by imatinib, or
synergistic resistance mediated by each drug’s upregula-
tion of p-glycoprotein [30]. Nonetheless, the hypothesized
normalization of IFP and tumor vasculature by pulse dose
imatinib improved only the efficiency and degree of re-
sponse to paclitaxel, not the duration. Resistance to pacli-
taxel prevailed at the expected time point.
We hypothesized that patients with high intratumoral
PDGF-B expression, an independent negative prognostic
indicator in NSCLC [10], may differentially benefit from
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PDGF-B may complete two pro-survival paracrine loops:
PDGFR-β stimulation of stromal fibroblasts resulting in
contraction of the extracellular matrix and elevated IFP;
and PDGFR-β activation of neovascular pericytes. Upre-
gulation of PDGF-B is a mechanism of chemotherapy re-
sistance in glioma [41]. In our small sample, tumor
PDGF-B expression was not associated with RR. How-
ever, higher PDGF-B expression scores were associated
with reduced PFS. Because adjunct imatinib resulted in
similar RR in patients with high or low expression of
PDGF-B, disruption of PDGF signaling may have over-
come intrinsic chemoresistance related to high IFP in
PDGF-B overexpressing tumors. However, the strategy
did not overcome the established association of high
PDGF-B expression with poor PFS. We speculate that
tumors with high PDGF-B expression may have a more
phenotypically normal vasculature, secondary to mature
pericyte coverage, limiting the anti-angiogenic benefit
from adjunct imatinib.
The combination of pulse dose imatinib and weekly
paclitaxel was adequately tolerated in this elderly cohort.
There were 2 protocol-related deaths, numerically iden-
tical to single agent paclitaxel in this population [15].
The rate of treatment-emergent Grade ≥ 3 cardiac ad-
verse events, which occurred in 4 patients (11.8%; 95%
CI 3.3-27.5%), obligates additional discussion. This rate
is numerically higher than reported for paclitaxel mono-
therapy in the elderly NSCLC population (5.7%; 95% CI
0.7-19.2%), although the confidence intervals overlap
[15]. In our study, 2 patients had documented decline in
systolic function, and 2 died from myocardial infarction
in the context of pre-existing coronary artery disease, a
prevalent comorbidity associated with increasing age in
NSCLC [42]. Direct injury to the cardiomyocyte is a
recognized toxicity of imatinib, consequent to c-Abl in-
hibition [43]. While causality cannot be ascribed to ima-
tinib for cardiac events in this study, there is an
established physiologic basis for potentiation of cardiac
toxicity. Caution is justified should this combination
undergo further development, particularly in patients
with pre-existing heart disease.
We conducted baseline measures of comorbidity,
frailty, and performance status, three components of
comprehensive geriatric assessment, to determine asso-
ciations with treatment vulnerability and survival. Med-
ical comorbidity, the burden of chronic disease
operationalized by the CCI, is associated with increased
surgical complications and poor survival in NSCLC
[43,44]. Frailty is the geriatric syndrome manifesting as
reduced physiologic reserve and adaptivity to environ-
mental stress. The VES-13 frailty score predicts mortal-
ity and hospitalization in ambulatory adults [27]. In
oncology, frailty may predict treatment vulnerabilitybetter than chronologic age or disability [45,46]. ECOG-
PS, a measure of cancer-related functional impairment,
is prognostic in elderly patients with advanced NSCLC;
moreover, an ECOG-PS of 2 is a better determinant of
poor outcome than advanced age in patients receiving
single agent docetaxel [47]. In our study, VES-13 was a
powerful predictor of poor PFS and OS, and performed
better than ECOG-PS which was associated only with
OS. Moreover, VES-13 identified 8 vulnerable patients
with a favorable ECOG-PS of 0 or 1. A combined vari-
able log rank test distinguished 2 groups with an 8
month absolute difference in OS. Specifically, non-frail
patients with ECOG-PS of 0 or 1 had a median survival
of 12 months vs. 4 months in others. Thus, assessment
of frailty with VES-13, a brief self-administered survey,
adds valuable information in the selection of elderly
NSCLC patients likely to experience survival benefit
from chemotherapy.
This study has several important limitations. First, the
absence of a randomized control group, exposed to
single-agent paclitaxel and studied with identical bio-
markers, particularly limits interpretation of our PDGF-
B data. Second, while the majority of patients consented
to optional tissue biomarkers, only 14 samples were
analyzable, increasing the likelihood of Type II error.
Third, the standard of care for unselected elderly
patients with advanced NSCLC is evolving away from
single agent chemotherapy. At design of this study,
advanced age (>70) was a relevant selection criterion for
single agent vs. platinum doublet chemotherapy, as
addressed in national U.S. guidelines [48]. In the inter-
val, an elderly-specific, randomized phase III trial docu-
mented superior survival from the combination of
carboplatin-paclitaxel vs. gemcitabine or vinorelbine
monotherapy [49]. Current guidelines emphasize patient
selection by performance status rather than chronologic
age [23]. Moreover, elderly patients are likely to benefit
from molecular selection by epidermal growth factor re-
ceptor and ALK gene mutations.
Conclusion
The regimen of pulse dose imatinib and weekly pacli-
taxel reached its primary endpoint, demonstrating an
encouraging RR in elderly patients with advanced
NSCLC. However, the benefit to adjunct imatinib was
limited to response, without an associated improvement
in PFS or OS. Reversal of elevated IFP and/or
normalization of tumor vasculature may be most benefi-
cial early in the course of cytotoxic chemotherapy. Given
the standard of care for elderly, molecularly-unselected
NSCLC patients has evolved to platinum doublet, as well
as the significant question of cardiac toxicity, further de-
velopment of this regimen does not appear justified.
Frailty, as measured by the VES-13, is a powerful
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should be further studied as a predictor of non-benefit
from cytotoxic chemotherapy.
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